Immunome
- Market cap
- 2.25B
- P/E (TTM)i
- -7.55
- P/Bi
- 4.29
- EPSi
- -2.43
- Div yieldi
- 0.00%
- 52W posi
- 34%
Anonymous reader poll. Unscientific, not investment advice.
Immunome ended the session at 19.10, down 1.11%. Its market capitalisation is about 2.25B, the #2671 most valuable US-listed company we track. Across 11 analysts the consensus rating is Buy, with an average price target of 35.40 (+85%). The shares sit 34% of the way up their 52-week range of 13.53 to 30.06.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 6 Sell calls were actually followed by a +25% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +8.2% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 14.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 19.31
- Open
- 18.94
- Day range
- 18.94 - 19.56
- Avg price
- 19.24
- Volume
- 1.16M
- Turnover
- 22.33M
- Turnover ratei
- 1.03%
- Volume ratioi
- 0.82
- Amplitudei
- 3.19%
- 52-week rangei
- 13.53 - 30.06
Valuation
- P/Ei
- -7.86
- P/E (TTM)i
- -7.55
- P/Bi
- 4.29
- EPSi
- -2.43
- Book value / shi
- 4.45
- Net profit
- -286.75M
- Net assets
- 525.11M
Share structure
- Market cap
- 2.25B
- Float capi
- 2.16B
- Shares out
- 118.00M
- Float sharesi
- 113.08M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-10-02
36.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+4.19M net over the window
Short interest
- Shares short
- 16.24M
- % of floati
- 14.30%
- Days to coveri
- 20.63
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Immunome (IMNM)?
Immunome last traded at 19.10. The quote on this page refreshes every few seconds while US markets are open.
What is Immunome's market cap?
About 2.25B.
What is the P/E ratio of Immunome?
The trailing twelve-month P/E is -7.55. The Valuation tab shows it against the stock's own five-year range.
Does Immunome pay a dividend?
Immunome does not currently pay a regular dividend.
Is Immunome a buy according to analysts?
The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 35.40, which implies 85.4% upside from the current price. This is not investment advice.
What is Immunome's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Immunome a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 06:41:31 · For reference only, not investment advice and not tailored to your situation.